Maravai LifeSciences reported Q4 2025 revenue of USD 49.9 million (-11.8%), with a net loss of USD 63.0 million and adjusted EBITDA of USD 0.5 million. TriLink revenue was USD 34.6 million (-17.4%), primarily reflecting a lack of high-volume CleanCap orders for commercial phase vaccine programs; excluding high-volume CleanCap, TriLink revenue increased 25.4% driven by GMP consumable products and CDMO GMP builds. Cygnus revenue was USD 15.3 million (+4.1%), supported by strength in HCP kits from core customers. For FY 2025, Maravai LifeSciences posted revenue of USD 185.7 million (-28.3%), a net loss of USD 230.8 million, and adjusted EBITDA of USD 31.2 million negative. TriLink FY revenue was USD 119.8 million (-39.0%), again impacted by a lack of high-volume CleanCap orders, while Cygnus FY revenue was USD 66.0 million (+5.0%) on strength in HCP kits, qualification services, and increased demand for MockV viral clearance kits. The company introduced FY 2026 guidance for revenue of USD 200 million to USD 210 million and adjusted EBITDA of USD 18 million to USD 20 million, and said its organizational restructuring and operating cost reduction are ahead of plan. Maravai LifeSciences also updated external reporting segment names, with Nucleic Acid Production and Biologic Safety Testing now reported as TriLink and Cygnus, respectively, with no change to segment composition or historical comparability.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maravai LifeSciences Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602251601BIZWIRE_USPR_____20260225_BW829291) on February 25, 2026, and is solely responsible for the information contained therein.
Comments